ADAM30 Activators are a group of chemical compounds that either directly or indirectly augment the functional activity of ADAM30 through several signalling pathways. NMS-P760 is a selective ADAM30 activator that directly induces ectodomain shedding of ADAM30 substrates like pro-TNFα by binding to and activating its protease domain, thereby enhancing ADAM30's cell signalling functions. Other compounds may indirectly activate ADAM30 by interfering with inhibitory pathways. For instance, Go6983 and Ro318220 are PKC inhibitors that could disinhibit ADAM30 signalling by preventing PKC-dependent phosphorylation and inhibition of ADAM30 protease activity. SB203580 inhibits p38 MAPK and so may reduce downstream inhibition of ADAM30 transcription.
Further indirect ADAM30 activators work through additional mechanisms. Ly294002 inhibits PI3K and may thus lift PI3K-dependent suppression of ADAM30 protease function. Thapsigargin and Bay K 8644 modulate calcium signalling in a way that could raise cytosolic calcium levels involved in calmodulin-mediated activation of ADAM30. Collectively, these ADAM30 Activators-whether directly targeting ADAM30 itself or altering inhibitory pathways-serve to facilitate enhanced ADAM30 function and signalling without needing to upregulate its expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A pan-PKC inhibitor that could potentially enhance ADAM30 activity by blocking PKC-dependent phosphorylation and inhibition of ADAM30, thus allowing ADAM30 to shed substrates and signal more freely. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
An irreversible inhibitor of Iκκβ that may enhance ADAM30 signalling by preventing Iκκβ inhibition of NF-κB and subsequent NF-κB-mediated inhibition of ADAM30 transcription. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
An inhibitor of EGFR tyrosine kinase activity that could hypothetically enhance ADAM30 signalling by lifting EGFR-mediated downregulation of ADAM30. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
An irreversible PKCβ inhibitor that may disinhibit ADAM30 signalling by preventing PKCβ-mediated phosphorylation and inhibition of ADAM30's protease activity. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
A Src tyrosine kinase inhibitor that could hypothetically boost ADAM30 function by limiting Src-mediated inhibition of ADAM30 protease activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A sarco/endoplasmic reticulum Ca2+-ATPase pump inhibitor that could hypothetically elevate cytosolic calcium levels involved in calmodulin-dependent activation of ADAM30. | ||||||